The collaboration between AstraZeneca and the money-magnet Moderna is giving its first steps. AstraZeneca is filing for authorization of a German Phase I trial, to assess an mRNA therapy for cardiometabolic diseases.
Therapies using mRNA have a lot of potential as biologics. Leading Biotechs in the field include CureVac (interview with its CCO here) and BioNTech, which recently published exciting results.
On the other side of the Atlantic, the also mRNA-focused Moderna Therapeutics has been very successful, as we discussed with CEO Bancel. It raised over $900M dollars in VC money. A key investor is Flagship Ventures, which has attracted AstraZeneca and other industry players.
In January, AstraZeneca struck a deal with Moderna to co-develop mRNA candidates in the clinical stage. The scope of the agreement included treatments for cardiovascular, metabolic and renal diseases as well as cancer.
Now,
